readthroughSign in
CompanyAPRENasdaqDoylestown, PA

Aprea Therapeutics

Aprea develops small-molecule inhibitors targeting cancer cell vulnerabilities.

10-QNov 4Latest SEC filing
Nov 2Latest story

November 2026

August 2026